COVME: Pilot Study Comparing Ventilation Modes During CPR With Mechanical Compression Device.

Sponsor
Technische Universität München (Other)
Overall Status
Completed
CT.gov ID
NCT03347175
Collaborator
(none)
30
1
3
25.2
1.2

Study Details

Study Description

Brief Summary

Comparison of three ventilation modes (volume controlled, BIPAP and CPAP) during cardiopulmonary re-suscitation with a mechanical compression device in the emergency room. Primary aim is to assess mean ventilation volume in the first 15 minutes after randomization.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Volume controlled ventilation
  • Procedure: Pressure controlled ventilation
  • Procedure: CPAP mode
N/A

Detailed Description

Mechanical compression devices are applied to grant continuous chest compressions and consequently blood flow during CPR (cardiopulmonary rescuscitation). Current guidelines, however, are lacking guidance of the optimal ventilation strategy in such scenarios. This may lead to lung injuries caused by high pressure levels in the chest while applying compression and ventilation simultaneously or hypoventilation. Consequently, this pilot study assesses iwhich ventilation mode is optimal. Patients will be assigned randomly to one of the three ventilation modes (Volume controlled, BiPAP-ASB, CPAP). Ventilation parameters will be continuously monitored for 15 minutes while blood gas analyses are taken as well. Further secondary outcome parameters will be assessed, e.g. hospital mortality.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Pilot Study: Comparison of Ventilation Modes During Cardio-pulmonary Resuscitation With a Mechanical Compression Device in the Emergency Room
Actual Study Start Date :
Nov 6, 2017
Actual Primary Completion Date :
Dec 12, 2019
Actual Study Completion Date :
Dec 12, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Volume controlled ventilation

Intervention1: Ventilation with Volume controlled ventilation

Procedure: Volume controlled ventilation
Volume controlled ventilation mode

Active Comparator: Pressure controlled ventilation

Intervention2: Ventilation with Pressure controlled ventilation

Procedure: Pressure controlled ventilation
Pressure controlled ventilation

Active Comparator: CPAP mode

Intervention3: Ventilation with Continuous Positive Airway Pressure mode only

Procedure: CPAP mode
CPAP mode only

Outcome Measures

Primary Outcome Measures

  1. mean tidal volume [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    mean tidal volume during the study period

Secondary Outcome Measures

  1. mean minute volume [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    mean minute volume during the study period

  2. etCO2 [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    Mean, final value and course of the parameter during the study period

Other Outcome Measures

  1. paO2 [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    Mean, final value and course of the parameter during the study period

  2. paCO2 [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    Mean, final value and course of the parameter during the study period

  3. Ventilation setting change [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    We will assess changes made in the ventilator settings (mode, tidal volume, frequency, FiO2 and PEEP) during the study period

  4. Ventilation setting change lateron [Starting after the end of Study Period (15 min after randomized ventilation mode was activated) till cardiopulmonary resuscitation is stopped by the treating team]

    We will assess changes made in the ventilator settings (mode, tidal volume, frequency, FiO2 and PEEP) after study period until the end of CPR

  5. Ventilation hours [Starting point = Activation of randomized ventilation mode till End point = time when patient is discharged from the hospital; ; approximately 3 weeks]

    Ventilation hours in the hospital

  6. 24h Survival [24h after randomization]

    Survival 24h after randomization

  7. Hospital Survival/Mortality [Starting point = Activation of randomized ventilation mode till End point = time when patient is discharged from the hospital; approximately 3 weeks]

    Hospital Survival/Mortality

  8. BGA [Study period = 15 min (Startpoint = Activating randomized ventilation mode Endpoint = 15 minutes after Starting point or end of CPR)]

    Blood gas analysis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • On-going out of hospital CPR in the Emergency Room

  • Tracheal intubated

  • Use of mechanical chest compression device

Exclusion Criteria:
  • If the treating team assumes that CPR will be ceased within the next 15 minutes

Contacts and Locations

Locations

Site City State Country Postal Code
1 Klinikum rechts der Isar Munich Bavaria Germany 81675

Sponsors and Collaborators

  • Technische Universität München

Investigators

  • Principal Investigator: Stefan J Schaller, MD, Klinik für Anaesthesiologie

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Stefan Schaller, Principal Investigator, Technische Universität München
ClinicalTrials.gov Identifier:
NCT03347175
Other Study ID Numbers:
  • COVME
First Posted:
Nov 20, 2017
Last Update Posted:
Feb 6, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Stefan Schaller, Principal Investigator, Technische Universität München

Study Results

No Results Posted as of Feb 6, 2020